ECONOMIC BURDEN OF DIABETES COMPLICATIONS IN ALGERIA: A REAL-WORLD BUDGET IMPACT ANALYSIS
Author(s)
Djenat Daci, PharmD1, Radia Bensemmane, PharmD1, ZOHEIR HAICHEUR, PharmD2.
1Département de pharmacie-Faculté de pharmacie, Université d’Alger 1, Alger, Algeria, 2Novo Nordisk, Algiers, Algeria.
1Département de pharmacie-Faculté de pharmacie, Université d’Alger 1, Alger, Algeria, 2Novo Nordisk, Algiers, Algeria.
OBJECTIVES: To estimate the economic burden associated with diabetes and its macrovascular and microvascular complications in Algeria using real-world data, and to assess their impact on healthcare expenditures.
METHODS: A retrospective, multicenter pharmacoeconomic study was conducted using data from 18,287 diabetic patients collected through the “Changing Diabetes Barometer” database. Costs related to treatment, monitoring, and management of complications were estimated from both public and private sector perspectives. A budget impact model was developed to extrapolate costs at the national level over a 3-year time horizon.
RESULTS: Among the study population, 10.3% of patients experienced at least one complication. Cardiovascular complications represented the highest cost per patient (€767), followed by peripheral artery disease (€659) and nephropathy (€355). Complications such as cardiovascular disease and retinopathy were associated with substantial incremental costs, representing up to 70-90% of baseline diabetes-related expenditures. National-level projections indicate a significant and increasing economic burden over the 3-year period.
CONCLUSIONS: Diabetes-related complications represent a major driver of healthcare costs in Algeria. These findings highlight the importance of effective prevention and disease management strategies to reduce the economic burden on the healthcare system.
METHODS: A retrospective, multicenter pharmacoeconomic study was conducted using data from 18,287 diabetic patients collected through the “Changing Diabetes Barometer” database. Costs related to treatment, monitoring, and management of complications were estimated from both public and private sector perspectives. A budget impact model was developed to extrapolate costs at the national level over a 3-year time horizon.
RESULTS: Among the study population, 10.3% of patients experienced at least one complication. Cardiovascular complications represented the highest cost per patient (€767), followed by peripheral artery disease (€659) and nephropathy (€355). Complications such as cardiovascular disease and retinopathy were associated with substantial incremental costs, representing up to 70-90% of baseline diabetes-related expenditures. National-level projections indicate a significant and increasing economic burden over the 3-year period.
CONCLUSIONS: Diabetes-related complications represent a major driver of healthcare costs in Algeria. These findings highlight the importance of effective prevention and disease management strategies to reduce the economic burden on the healthcare system.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE325
Topic
Economic Evaluation, Epidemiology & Public Health, Real World Data & Information Systems
Topic Subcategory
Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas